Recombinant ErbB2/Her2 (Trastuzumab Biosimilar) anticorps

N° du produit ABIN7200659

Cet anticorps Souris Monoclonal détecte spécifiquement ErbB2/Her2 (Trastuzumab Biosimilar) dans FACS et in vivo. Il présente une réactivité envers Humain.

Aperçu rapide pour Recombinant ErbB2/Her2 (Trastuzumab Biosimilar) anticorps (ABIN7200659)

Antigène: ErbB2/Her2 (Trastuzumab Biosimilar)

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp ErbB2/Her2 (Trastuzumab Biosimilar) est non-conjugé

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Clone: 4D5-8

Détail du produit anti-ErbB2/Her2 (Trastuzumab Biosimilar) anticorps

Fonction: Trastuzumab Biosimilar, HER2 Monoclonal Antibody

Specificité: The monoclonal antibody trastuzumab biosimilar specifically binds to the human HER2 / ErbB-2 / c-neu.

Attributs du produit: Recombinant Humanized IgG1 Monoclonal Antibody.

Purification: Protein A affinity column

Pureté: > 95% by SDS-PAGE under reducing conditions and HPLC.

Stérilité: 0.2 μm filtered

niveau d'endotoxine: < 1 EU per 1 mg of the protein by the LAL method.

Immunogène: The monoclonal antibody trastuzumab biosimilar was produced in the trastuzumab biosimilar CHO stable cell line.

Isotype: IgG1 kappa

Information d'application

Indications d'application: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by trastuzumab.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 21.2 mg/mL

Buffer: PBS, pH 7.4, no stabilizers or preservatives.

Agent conservateur: Without preservative

Conseil sur la manipulation: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Stock: -20 °C

Stockage commentaire: 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.

Date de péremption: 12 months

Détails sur ErbB2/Her2 (Trastuzumab Biosimilar)

Antigène: ErbB2/Her2 (Trastuzumab Biosimilar)

Classe de substances: Biosimilar

Sujet: Trastuzumab, a humanized monoclonal antibody, interferes with the HER2/neu receptor and is mainly used to treat certain breast cancers, especially HER2-positive metastatic breast cancer. Combined with chemotherapy, trastuzumab increases both survival and response rate.

There are four closely related receptor tyrosine kinases in the ErbB family of receptors: EGFR (ErbB-1; HER1 in humans), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Bound by members of the epidermal growth factor family (EGF-family) of extracellular protein ligands, the HER receptors embedded in the cell membrane promote cell growth and division by turning genes on and off. The HER2 pathway stimulates cell proliferation if it normally functions; when HER2 is overexpressed, cell growth accelerates beyond its normal limits, which happens in some cancers, notably certain types of breast cancer.